News

The prevalence of smoking among African American young adults “catches up” with other groups despite the low rate among Black youth. The ban on menthol may affect this and other aspects of smoking patterns among Black Americans.

Treating insomnia with commonly prescribed, older generation medications increases health care resource utilization and costs in patients with comorbid conditions.

The AstraZeneca drug is the first SGLT2 inhibitor approved for chronic kidney disease regardless of whether the patient has diabetes.

Oncology Analytics senior vice president Laura Bobolt discusses the new indication for Trodelvy and other matters.

Chemo in combination with immunotherapy was preferable to immunotherapy alone in patients with a mutation of the KRAS gene and high levels of programmed cell death ligand 1, according to findings reported in JAMA Oncology.

Global drug spending — excluding COVID-19 vaccines — is expected to reach an estimated $1.6 trillion by 2025, a new report says.

The antibody-conjugate is also approved as a treatment for metastatic triple negative breast cancer.

The jury is still out, but the evidence is accumulating that people with HIV with comorbidities such as diabetes may be at greater risk for hospitalization from COVID-19.

Improvements in prevention toward HIV is starting in Texas through Texas Health Action. The health organization is creating a virtual HIV prevention service available toward HIV care and gender affirming care in rural areas.

A recent study from American Accounting Association finds health insurance companies are overestimating costs associated with patient care to avoid triggering rebate provisions in the Affordable Care Act.

The administration gets a A-, B+ on most healthcare matters from Marc Samuels, CEO of ADVI and a member of the MHE editorial advisory board.

New starts fell off sharply last spring and the flu season "all but disappeared," according a summary of CVS Caremark's 2020 drug spend report.

Vagner shares best work/life balance practices for parents during a new phase of COVID-19 as their children are back in school. The vice president of People at Maven, a virtual clinic for women's and family health, also shares some well-being tips that work for him as a parent.

As market forces visibly disrupt healthcare (less access to cheap capital, reimbursement pressures, rising demand for services in the face of constrained supply), digitally transforming core processes is not merely an option any more.

The pandemic is expected to have a significant effect on drug costs this year and into 2022, a new report says.

Dan Ollendorf, Ph.D., M.P.H.,of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center, is co-author of a new book, The Right Price, A Value-Based Prescription for Drug Costs.

In this latest episode of Tuning In to the C-Suite’s Meet the Board podcast series, Managed Healthcare Executive's Senior Editor Peter Wehrwein and Associate Editor Briana Contreras spoke with MHE Editorial Advisory Board member, Doug Chaet. Chaet is president of Value Evolutions and chairman of the American Association of Integrated Healthcare Delivery Systems. In this conversation, the editors were able to learn more about the loyal board member and his background in healthcare toward his managed care career and were able to hear his thoughts on particular topics such as value-based care, ACOs and more.

Six-year plan to invest $11.5 billion with donor support to accelerate research and treatment worldwide for children with catastrophic diseases.

Much of the data that AI depends on is tainted with racial bias.

The major depressive disorder (MDD) market is expected to soar to $7.87 billion by 2029.

Some of the usual suspects are on the list. And population health itself is trending as a competitive business and an area of study.

Healthcare providers can consider these strategies when developing a plan to transition to more frequent in-office treatment.

Program could be easily implemented at tribal clinics, says lead author.

Paying attention to the social determinants of health may be a powerful way of improving cardiovascular outcomes.

Centralized resource streamlines information sharing between health plans, Medicaid agencies and third-party app developers ahead of CMS Interoperability and Patient Access rule deadlines.

FDA has recently approved therapies targeting MET exon 14 skipping mutations.